With around 1.8 million new cases per year, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer deaths globally. Early diagnosis of cancer is crucial for increasing survival rates and reducing treatment costs. Based on our patented detection concept, we will develop disposable, inexpensive optical biosensors for the label-free detection of cancer biomarkers, aiming to enhance early diagnosis while supporting sustainability goals such as improving public health outcomes, reducing healthcare costs, and increasing accessibility to diagnostic tools in underserved communities. This can be seen as a valuable addition to existing diagnostic methods, enabling quick follow-ups for cancer patients. Furthermore, our biosensor concept is versatile and can be adapted for early diagnosis of other diseases, such as rheumatoid arthritis. During the BB programme, we will first validate our concept on cancer patient blood samples and also build a solid market analysis and business model.
